P/E ratio for Mirati Therapeutics (MRTX)
P/E ratio as of May 2024 (TTM): -4.58
According to Mirati Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.57878. At the end of 2022 the company had a P/E ratio of -3.44.
P/E ratio history for Mirati Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.44 | -73.82% |
| 2021 | -13.1 | -52.47% |
| 2020 | -27.6 | 20.92% |
| 2019 | -22.8 | 70.74% |
| 2018 | -13.4 | 104.58% |
| 2017 | -6.54 | 478.38% |
| 2016 | -1.13 | -86.44% |
| 2015 | -8.34 | 45.87% |
| 2014 | -5.72 | 64.23% |
| 2013 | -3.48 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 TravelCenters of America TA | 9.03 | -297.29% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | -3.33 | -27.20% | Bahamas |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.